Ibnsina Pharma (EGX:ISPH)
10.46
-0.04 (-0.38%)
At close: Mar 15, 2026
Ibnsina Pharma Balance Sheet
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 920.19 | 835.86 | 1,131 | 541.21 | 468.54 |
Trading Asset Securities | 55 | - | - | - | - |
Cash & Short-Term Investments | 975.19 | 835.86 | 1,131 | 541.21 | 468.54 |
Cash Growth | 16.67% | -26.08% | 108.93% | 15.51% | 72.97% |
Accounts Receivable | 21,560 | 16,267 | 9,761 | 5,775 | 5,743 |
Other Receivables | - | 3.04 | 0.01 | 0.07 | - |
Receivables | 21,560 | 16,270 | 9,761 | 5,775 | 5,743 |
Inventory | 8,246 | 6,575 | 3,195 | 2,614 | 2,359 |
Prepaid Expenses | 51.74 | 24.34 | 28.39 | 38.8 | 46.45 |
Other Current Assets | 1,694 | 1,769 | 1,823 | 1,543 | 1,061 |
Total Current Assets | 32,527 | 25,474 | 15,937 | 10,511 | 9,678 |
Property, Plant & Equipment | 3,076 | 2,672 | 2,184 | 2,156 | 1,468 |
Long-Term Investments | - | - | 15.92 | - | - |
Other Intangible Assets | 236.36 | 218.37 | 219.02 | 30.18 | 15.3 |
Long-Term Deferred Tax Assets | 360.36 | 228.73 | 114.4 | 82 | 59.39 |
Total Assets | 36,214 | 28,642 | 18,550 | 12,864 | 11,284 |
Accounts Payable | 6,016 | 5,833 | 3,661 | 1,593 | 1,399 |
Accrued Expenses | 196.1 | 147.65 | 123.05 | 63.21 | 43.42 |
Short-Term Debt | 5,170 | 4,379 | 3,165 | 2,290 | 1,568 |
Current Portion of Long-Term Debt | 19,563 | 14,402 | 8,673 | 6,339 | 5,910 |
Current Portion of Leases | 242.69 | 230.65 | 117.94 | 90.41 | 71.2 |
Current Income Taxes Payable | 256.99 | 203.05 | 79.91 | 26.73 | 59.55 |
Current Unearned Revenue | 38.89 | 38.16 | 17.96 | 16.77 | 15.32 |
Other Current Liabilities | 249.12 | 193.44 | 85.74 | 50.93 | 335.18 |
Total Current Liabilities | 31,732 | 25,427 | 15,924 | 10,470 | 9,401 |
Long-Term Debt | 891.23 | 47.46 | 556.02 | 852.18 | 204.83 |
Long-Term Leases | 806.09 | 1,136 | 620.42 | 281.67 | 224.8 |
Other Long-Term Liabilities | - | - | - | 0 | - |
Total Liabilities | 33,430 | 26,610 | 17,101 | 11,604 | 9,831 |
Common Stock | 252 | 252 | 252 | 279.04 | 240 |
Additional Paid-In Capital | 237.41 | 237.41 | 237.41 | 277.5 | 277.5 |
Retained Earnings | 2,466 | 1,713 | 1,131 | 901.63 | 948.62 |
Treasury Stock | -171.64 | -171.64 | -171.64 | -198.69 | -14.4 |
Total Common Equity | 2,784 | 2,031 | 1,449 | 1,259 | 1,452 |
Minority Interest | 0 | 0 | 0 | 0.39 | 1.77 |
Shareholders' Equity | 2,784 | 2,031 | 1,449 | 1,260 | 1,453 |
Total Liabilities & Equity | 36,214 | 28,642 | 18,550 | 12,864 | 11,284 |
Total Debt | 26,672 | 20,195 | 13,133 | 9,853 | 7,979 |
Net Cash (Debt) | -25,697 | -19,359 | -12,002 | -9,312 | -7,510 |
Net Cash Per Share | -25.49 | -19.21 | -11.91 | -9.24 | -5.77 |
Filing Date Shares Outstanding | 1,008 | 1,008 | 1,008 | 1,008 | 1,226 |
Total Common Shares Outstanding | 1,008 | 1,008 | 1,008 | 1,008 | 1,226 |
Working Capital | 794.75 | 47.06 | 12.98 | 41.39 | 276.74 |
Book Value Per Share | 2.76 | 2.02 | 1.44 | 1.25 | 1.18 |
Tangible Book Value | 2,548 | 1,813 | 1,230 | 1,229 | 1,436 |
Tangible Book Value Per Share | 2.53 | 1.80 | 1.22 | 1.22 | 1.17 |
Land | 93.75 | 93.75 | 93.75 | 93.75 | 93.75 |
Buildings | 887.51 | 847.39 | 807.75 | 724.3 | 692.7 |
Machinery | 1,246 | 969.85 | 828.47 | 648.61 | 612.95 |
Construction In Progress | 832.14 | 210.77 | 427.51 | 944.81 | 242.88 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.